These models are established in immunodeficient mice engrafted with CD34+ hematopoietic stem cells (HSCs), allowing for the characterization of distinct circulating and tumor-infiltrating immune cell profiles, as well as the observation of diverse anti-tumor efficacy of PD-1/PD-L1 ICIs16–18. Here, CD34 is linked to neoplasm.